LTR Pharma (ASX:LTP) secured Human Research Ethics Committee approval from independent ethics committee Bellberry for the Spontan phase 2 pharmacokinetic and multiple-dose clinical study, according to a Wednesday filing with the Australian bourse.

Spontan is the company's intranasal spray for the potential treatment of erectile dysfunction.

The approval allows the company to progress toward patient recruitment in 2026, the filing said.

Initial data is anticipated in the second quarter of 2026, with complete study results expected in the middle of the same year, per the filing.

Shares rose more than 2% in afternoon trade Wednesday.